Palomar Medical (PMTI) Reports Q2 Adj-EPS of $0.10, Beats by 1c
More News related to PMTI
- Maxim Upgrades Palomar Medical (PMTI) to Buy
- Palomar's Hair Removal Lawsuit Against Candela Stayed Pending Re-Examination By United States Patent Office
- Reliant Technologies, and Palomar Medical Technologies, Announce Launch of a Fractional Technology Licensing Program
- Palomar Medical Technologies and Reliant Technologies Announce Launch of a Fractional Technology Licensing Program
- Matrix Lighthouse Rating Changes 11/05
More News related to Earnings
- BMO Upgrades Spectrum Brands (SPC) to Market Perform
- Maxim Upgrades Palomar Medical (PMTI) to Buy
- RBC Capital Upgrades DSP Group (DSPG) to Sector Perform
- UBS Upgrades Morgans Hotel Group (MHGC) to Buy
- Janney Montgomery Scott Upgrades Wright Express Corp (WXS) to Buy.
Palomar Medical Technologies, Inc. (Nasdaq: PMTI) reports Q2 adj-EPS of $0.10, 1 cent better than the analyst estimate of $0.09. Revenues for the quarter were $23.1 million, versus the consensus of $24.69 million.
Palomar Medical Technologies, Inc. and its subsidiaries engage in the research, development, manufacture, distribution, and sale of laser and light-based products and related disposable items and accessories for medical and cosmetic treatments.
Related Categories
EarningsStocks Mentioned
+0.85Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
